Two‐year outcomes after percutaneous coronary intervention with drug‐eluting stents or bare‐metal stents in elderly patients with coronary artery disease
2020
Lafont, Alexandre | Sinnaeve, Peter | Cuisset, Thomas | Cook, Stéphane | Sideris, Giorgios | Kedev, Sasko | Carrié, Didier | Hovasse, Thomas | Garot, Philippe | El Mahmoud, Rami | Spaulding, Christian | Helft, Gérard | JOSE F. DIAZ, FERNANDEZ | Brugaleta, Salvatore | Pinar-Bermudez, Eduardo | Mauri, Josepa | Commeau, Philippe | Teiger, Emmanuel | Bogaerts, Kris | Sabate, Manel | Morice, Marie Claude | Varenne, Olivier
Objectives Report the results at 2 years of the patients included in the SENIOR trial. Background Patients above 75 years of age represent a fast-growing population in the cathlab. In the SENIOR trial, patients treated by percutaneous coronary intervention (PCI) with drug eluting stent (DES) and a short duration of P2Y12 inhibitor (1 and 6 months for stable and unstable coronary syndromes, respectively) compared with bare metal stents (BMS) was associated with a 29% reduction in the rate of all-cause mortality, myocardial infarction (MI), stroke, and ischaemia-driven target lesion revascularization (ID-TLR) at 1 year. The results at 2 years are reported here. Methods and Results We randomly assigned 1,200 patients (596[50%] to the DES group and 604[50%] to the BMS group). At 2 years, the composite endpoint of all-cause mortality, MI, stroke and ID-TLR had occurred in 116 (20%) patients in the DES group and 131 (22%) patients in the BMS group (RR 0.90 [95%CI 0.72-1.13],p= .37). IDTLR occurred in 14 (2%) patients in the DES group and 41 (7%) patients in the BMS group (RR 0.35 [95%CI 0.16-0.60],p= .0002). Major bleedings (BARC 3-5) occurred in 27(5%) patients in both groups (RR 1.00, [95%CI 0.58-1.75],p= .99). Stent thrombosis rates were low and similar between DES and BMS (0.8 vs 1.3%, (RR 0.52 [95%CI 0.01-1.95],p= .27). Conclusion Among elderly PCI patients, a strategy combining a DES together with a short duration of DAPT is associated with a reduction in revascularization up to 2 years compared with BMS with very few late events and without any increased in bleeding complications or stent thrombosis.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par National Institute for Agricultural Research
Découvrez la collection de ce fournisseur de données dans AGRIS